Last updated: July 29, 2026
Promethazine hydrochloride (plain) is a long-established, off-patent first-generation antihistamine (phenothiazine class) with steady baseline demand driven by allergy symptom control, nausea and vomiting indications, and broad generic availability. Financial trajectory is characterized by low margin compression, episodic price resets from new generic launches, periodic supply and quality interruptions, and recurring competitive intensity from multiple ANDA players. The “plain” dosage forms (not extended-release, not fixed-dose combinations) face the most direct pricing pressure because they are easy to replicate and typically have minimal formulation IP barriers.
How big is the promethazine hydrochloride market and what drives demand for plain products?
Promethazine hydrochloride demand is driven by a mix of OTC and prescription use, with prescription pull supported by antiemetic use (nausea/vomiting), antihistamine use (allergic symptoms), and peri-procedural and emergency-department usage patterns. The market is also supported by hospitals and acute-care settings that maintain formulary stock for symptomatic treatment.
Key demand drivers
- Therapeutic breadth. Promethazine is used across allergy and emesis management workflows, which supports recurring consumption even as newer agents shift preference in some segments.
- Generic substitution at scale. “Plain” promethazine products are usually interchangeable at the therapeutic class level, which sustains volume but pressures pricing.
- Formulary inertia and stock management. Hospitals reorder based on historical usage, purchasing contracts, and inventory reliability, which can keep unit volumes stable even as prices erode.
Market structure
- Predominantly multi-source generic supply.
- Fragmented prescriber base across outpatient and inpatient settings.
- Pricing and availability are sensitive to manufacturing line uptime, raw material availability, and regulatory actions affecting specific manufacturers.
What are the revenue and margin dynamics for generic promethazine hydrochloride plain?
Financial performance in promethazine plain is typically dominated by:
- volume stability (units sold),
- price erosion (average selling price pressure), and
- inventory and supply reliability effects (opportunity for temporary price increases when supply tightens).
Typical financial pattern
- Pre-generic era: brand pricing supported higher revenue but is long past for promethazine plain.
- Post-generic saturation: ASP declines toward generic benchmarks; margins depend on manufacturing efficiency and contract pricing.
- Supply disruptions: short-term price spikes can occur, but these usually do not reverse long-run downward trends because competitors can ramp once bottlenecks clear.
Commercial reality
- With widespread generic availability, “financial trajectory” tends to track industry generic market pricing rather than product-specific innovation.
- Product-level outperformance is usually tied to NDC-specific positioning, contracted hospital accounts, and execution (lot release speed, reliable supply, and compliance performance).
Which dosage forms and strengths matter most for promethazine hydrochloride plain revenue?
Promethazine plain is sold in multiple conventional formulations. Revenue concentration often follows where utilization is highest and where supply competition is intense.
High-velocity form factors
- Oral tablets and oral syrup/solution: broad outpatient use for allergy and nausea.
- Injectable promethazine (plain): institutional use is typically higher-value per unit but also subject to tighter supply management and sterility assurance cost.
- Rectal formulations (if marketed/available): niche utilization that depends on local formularies.
Pricing pressure profile
- Oral forms usually experience sharper price compression due to abundant multi-source offerings.
- Injectable forms can show more volatility because sterile manufacturing constraints raise effective supply barriers, even when generic replication is feasible.
How do price erosion and generic competition shape promethazine hydrochloride plain ASP over time?
Promethazine hydrochloride plain faces ongoing competition from multiple ANDA-generics. In this setting:
- ASP declines gradually or in steps as additional competitors enter and as contract renewals reset pricing.
- Differentiation is limited, so competitive advantage comes from supply reliability, scale manufacturing, and distribution relationships.
What typically causes step-downs
- Multiple new generic launches in the same strength/form lead to rapid bid competition.
- Increased wholesaler and group purchasing organization (GPO) pressure reduces contract price bands.
- Regulatory actions that consolidate supply into fewer qualified sources can temporarily raise pricing before normalization.
What can temporarily lift pricing
- Manufacturing downtime, sterility failures (for injectables), or quality holds affecting specific labelers.
- Regional supply gaps that trigger short-term substitute ordering until full availability returns.
Is promethazine hydrochloride plain protected by patents or market exclusivity today?
For promethazine hydrochloride plain, core active ingredient protection from original innovation is long expired. Commercial protection usually comes from:
- formulation/processing patents (if any still active for specific dosage forms or manufacturing processes),
- FDA exclusivity tied to specific changes (less common for long-established products), and
- regulatory listing-based exclusivity like 505(b)(2) or pediatric exclusivity only if applicable to a particular reformulation or NDA.
In practice, for the plain drug, these protections are generally not sufficient to prevent broad generic substitution.
What is the Orange Book status of promethazine hydrochloride plain?
Orange Book status for plain promethazine hydrochloride products generally reflects multiple listed ANDA equivalents across strengths and dosage forms rather than a single dominant protected product. Patent coverage, where present, tends to be:
- narrow to a specific dosage form or process,
- difficult to enforce against bioequivalent generic versions that do not practice the claimed formulation/method.
This usually translates into a stable pipeline of generic supply rather than sustained exclusivity-driven pricing power.
When does promethazine hydrochloride lose exclusivity and what does that mean for generics?
The economic “exclusivity” milestone for promethazine hydrochloride plain has effectively been realized years ago through the transition to generic supply. The current risk for branded-like pricing is not a future exclusivity expiration date. It is instead:
- ongoing ANDA churn,
- incremental entry by additional manufacturers,
- and periodic market reset when supply conditions change.
How many generic companies compete for promethazine hydrochloride plain and what does that do to pricing?
The competitive set is typically broad due to:
- easy-to-make characteristics for conventional dosage forms,
- historically low regulatory novelty,
- and long availability of generic filing templates.
Pricing implication
- More competitors generally means a tighter price band for most strengths and forms.
- The best surviving labelers are the ones that can keep consistent supply and land preferred distribution contracts.
What generic entry risks exist for promethazine hydrochloride plain (Paragraph IV, 180-day exclusivity)?
For plain promethazine hydrochloride, the dominant market behavior is not tied to frequent Paragraph IV waves. The likely generic entry model is:
- straightforward ANDA submissions,
- limited patent barriers,
- and entry that competes on logistics, contracts, and release performance rather than litigation-driven delay.
Paragraph IV challenges can occur for specific NDCs if a listed method-of-use or formulation patent exists. The commercial impact would be concentrated in those specific strengths or dosage forms where the patent listing blocks “at-risk” substitution.
What patent estate issues could still affect promethazine hydrochloride plain launches?
Even though the active ingredient is off-patent, residual patent coverage can exist for:
- specific manufacturing processes,
- specific formulations or excipient systems, or
- specific methods of use tied to a narrow claim set.
For a “plain” drug, this estate is usually not large enough to create sustained launch delay across the entire product line. It can still matter in narrow NDC segments where a listed patent blocks generic labeling.
How does promethazine hydrochloride injection compare with oral forms in market and financial performance?
Injectable promethazine plain tends to have:
- higher institutional demand but more complex manufacturing and quality constraints,
- more meaningful supply sensitivity when sterility assurance capacity is constrained,
- potentially higher pricing volatility during supply disruptions.
Oral forms tend to:
- have more stable supply,
- attract more generic competition on a price basis,
- and show lower unit economics but higher total volume.
What FDA regulatory status factors affect financial trajectory (Bioavailability, labeling, shortages)?
Key regulatory factors that can influence financial outcomes include:
- ANDA approval cadence for new labelers and line expansions,
- product discontinuations by specific manufacturers that temporarily improve pricing for remaining supply,
- shortage classifications or FDA communications that shift allocation decisions,
- labeling changes that can require line relabeling and can cause temporary supply friction.
In plain promethazine, regulation rarely supports long-lived premium pricing, but it can create short-to-medium term market imbalances.
What manufacturing/IP barriers still matter for promethazine hydrochloride plain?
For conventional formulations, manufacturing barriers are mainly:
- sterile manufacturing capacity (injectable),
- quality systems for consistent release,
- and supply chain constraints for consistent bulk material availability.
IP barriers, where present, tend to be narrow and usually do not stop broad market access unless a specific NDC is tied to a unique, still-active claim set.
How do supply shortages and recalls translate into financial swings?
Financial swings generally follow this pattern:
- A quality event reduces available lots for a labeler.
- Wholesalers and GPOs allocate limited inventory to higher-priority accounts.
- ASP rises in the short term across constrained channels.
- Competitors or restarting manufacturing reduce pricing back to competitive levels.
Because promethazine is commoditized, these spikes tend to be short and localized.
What does the competitive landscape look like for promethazine hydrochloride plain?
Competitive dynamics are typically characterized by:
- multiple interchangeable ANDA products,
- contract and GPO leverage driving award cycles,
- and NDC-level competition where distributors prefer reliable supply.
The labelers most likely to win financially are those that:
- maintain consistent lot release,
- minimize out-of-stock risk,
- and hold strong distribution relationships.
What are the likely financial scenarios for promethazine hydrochloride plain over the next 3 to 5 years?
Base case
- Continued generic price compression with stable demand.
- Revenue growth driven primarily by unit volume and contract dynamics, not pricing.
Bull case
- Intermittent supply constraints in specific forms and/or strengths create temporary pricing uplift.
- One or more major labelers face extended production delays, improving allocation value for remaining suppliers.
Bear case
- Market pricing resets downward due to increased labeler competition, expanded capacity, or contract renegotiations.
- Quality or compliance issues concentrate supply into fewer qualified sources temporarily, then resolve as more capacity returns, compressing realized pricing.
Key Takeaways
- Promethazine hydrochloride plain is a commoditized, off-patent generic market with pricing pressure driven by multi-source competition.
- Financial trajectory is dominated by ASP compression, contract resets, and supply reliability rather than innovation-led differentiation.
- Injectable forms can show more pricing volatility due to sterility manufacturing constraints and shortage dynamics; oral forms typically track stable volume with ongoing price erosion.
- Long-run growth is most likely to come from volume and distribution execution, not from patent- or exclusivity-led premium economics.
FAQs
- Does promethazine hydrochloride plain have 180-day exclusivity opportunities for generic entry?
- Which NDCs for promethazine hydrochloride plain are most exposed to price resets during contract renewals?
- How do FDA shortage communications for promethazine impact wholesaler allocation and realized pricing?
- Are there still formulation or method patents that can delay generic labeling for specific promethazine strengths?
- How does the revenue profile of promethazine injection compare with oral syrup tablets in generic markets?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-29).
- FDA. Drug Shortages. (Accessed 2026-07-29).
